Lifeboat Foundation

GTB-3550 is the company’s first TriKE® product candidate that was evaluated in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies. Phase 1 clinical trials were shown to be both safe and well-tolerated, as well as proving the molecule’s clinical concept and providing a framework for future product candidates.

GTB-3650 is a second-generation protein developed to treat AML and MDS. It has replaced GTB-3550 and utilizes camelid nanobody technology. GTB3650 has successfully completed pre-clinical trials and is in the good manufacturing process (GMP) stage, which is usually the last developmental milestone before progressing into phase 1 clinical trials.

Angel provides driver and customer support. Naomi teaches high school students. But they are not humans. They’re HumAIns, artificial intelligence (AI) agents.

Designed to handle unscripted communication tasks autonomously and proactively, Angel and Naomi use human-like thought processes to lead conversations instead of merely answering questions. And they get smarter with time and experience.

Continue reading “The AI customer-support agents that can think and act like humans” »

This is according to a press release by the institution published on Tuesday.

The PV-leaf

Called PV-leaf, the innovation “uses low-cost materials and could inspire the next generation of renewable energy technologies.”

WASHINGTON — Artificial intelligence startup Wallaroo Labs won a $1.5 million contract from the U.S. Space Force to continue the development of machine learning models for edge computers in orbit.

The New York-based company, known as Wallaroo.ai, is partnered with New Mexico State University for the Small Business Technology Transfer Phase 2 contract, announced Aug. 15. The team last year won a Phase 1 award.

Wallaroo.ai created a software platform that helps businesses assess the performance of AI applications when deployed on edge computers.

Can you recognize someone you haven’t seen in years, but forget what you had for breakfast yesterday? Our brains constantly rearrange their circuitry to remember familiar faces or learn new skills, but the molecular basis of this process isn’t well understood. Today, scientists report that sulfate groups on complex sugar molecules called glycosaminoglycans (GAGs) affect “plasticity” in the brains of mice. Determining how GAGs function could help us understand how memory and learning work in humans, and provide ways to repair neural connectivity after injuries.

The researchers will present their results today at the fall meeting of the American Chemical Society (ACS).

The sugars that sweeten fruits, candies or cakes are actually just a few simple varieties of the many types of sugars that exist. When strung together, they can make a wide array of complex sugars. GAGs are formed by then attaching other chemical structures, including sulfate groups.

Exactly how, and how much, the unconscious processing of information influences our behavior has always been one of the most controversial questions in psychology. In the early 20th century, Sigmund Freud popularized the idea that our behaviors are driven by thoughts, feelings, and memories hidden deep within the unconscious mind — an idea that became hugely popular, but that was eventually dismissed as unscientific.

Modern neuroscience tells us that we are completely unaware of most brain activity, but that unconscious processing does indeed influence behavior; nevertheless, certain effects, such as unconscious semantic “priming,” have been called into question, leading some to conclude that the extent of unconscious processing is limited.

A recent brain scanning study now shows that unconsciously processed visual information is distributed to a wider network of brain regions involved in higher-order cognitive tasks. The results contribute to the debate over the extent to which unconscious information processing influence the brain and behavior and led the authors of the study to revise one of the leading theories of consciousness.

Sean Carroll is a theoretical physicist and philosopher who specializes in quantum mechanics, cosmology, and the philosophy of science. He is the Homewood Professor of Natural Philosophy at Johns Hopkins University and an external professor at the Sante Fe Institute. Sean has contributed prolifically to the public understanding of science through a variety of mediums: as an author of several physics books including Something Deeply Hidden and The Biggest Ideas in the Universe, as a public speaker and debater on a wide variety of scientific and philosophical subjects, and also as a host of his podcast Mindscape which covers topics spanning science, society, philosophy, culture, and the arts.

#physics #quantum #philosophy #mathematics.

Continue reading “Sean Carroll | The Many Worlds Interpretation & Emergent Spacetime | The Cartesian Cafe w Tim Nguyen” »

Finding supermassive black holes with masses billions of times greater than the sun under a billion years after the Big Bang has scientists confused how these cosmic titans got so big so quickly.

DURHAM – A big licensing deal potentially worth hundreds of millions of dollars with an Austrlia-based company at the same time also has triggered what Precision Biosciences calls a “right-sized” organization of the company.

“Prior to the announcement, we had 190 employees, with 110 going forward with Precision. Most of the 80 employees went with Imugene, with the remainder parting ways with a reduction in force,” Mei Burris, director of investor relations and finance for the company,” told WRAL TechWire.

What “right-sized” means was not immediately explained in the company’s announcement Tuesday night after the markets closed. The company’s stock is trading at under $1 and it lost $12 million in its most recent quarter ending June 30.